Efficacy and safety of lenvatinib plus everolimus in metastatic renal cell carcinoma after immune checkpoint and VEGFR tyrosine kinase inhibitors. This is an ASCO Meeting Abstract from the 2025 ASCO ...

Hepatocellular carcinoma is a leading cause of cancer-related death globally. The treatment of hepatocellular carcinoma is complex, with diverse therapeutic approaches and their combinations available ...

Bone metastases are cancers that have spread (metastasized) from other tissues in the body through the blood or lymphatic systems to the bone marrow. Bone metastases form the main type of bone ...

Hepatocellular ... milieu conducive to cancer progression (Chen and Song, 2019). CAFs are central to maintaining ECM homeostasis, synthesizing and secreting ECM proteins under pathological conditions ...

Combined locoregional and systemic therapies might enhance treatment outcomes compared with either option alone. This Series paper summarises the existing data on locoregional and systemic therapies ...

Background: Hepatocellular carcinoma (HCC) is one of the most prevalent and fatal cancers globally ... which can contribute to tumor progression, metastasis, and resistance to chemotherapy. In our ...

Background: Hepatic arterial infusion chemotherapy (HAIC) has emerged as a promising treatment for unresectable hepatocellular carcinoma (HCC). However, the safety profiles of HAIC and its various ...

If you have secondary bone cancer, this is not the right section for you. You need to look at the section for your type of primary cancer which is named after the part of your body where your cancer ...

TNM stands for Tumour, Node, and Metastasis. It's one of the staging systems for bone cancer. Doctors may also use the number staging system. The stage of a cancer tells the doctor about its size and ...

Sorafenib is US FDA approved for the treatment of advanced renal cell carcinoma and unresectable hepatocellular carcinoma ... activity in the treatment of metastatic breast cancer (MBC).

Belzutifan monotherapy in Chinese patients (pts) with von Hippel-Lindau (VHL) disease–associated tumors: Results of LITESPARK-015 study. This is an ASCO Meeting Abstract from the 2025 ASCO ...